![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif)
yttrium Y 90 daclizumab A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity. Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes. As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif) | Y90 daclizumab Y90 MOAB anti-Tac | | ![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509163141im_/http://www.cancer.gov/images/spacer.gif) |